For both tau and TDP-43 directed therapies, there is a broader question raised by the presence of multiple disease subtypes (for example, CBD, PSP and PiD in FTLD-tau and type A-D for FTLD-TDP). Here, MAPT is linked to supranuclear palsy, progressive, 1.